|
Market Closed -
Nasdaq
04:00:00 2026-09-03 pm EDT
|
5-day change | 1st Jan Change | ||
| 444.12 USD | +0.29% |
|
+1.63% | +35.69% |
| 05:32am | Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating | MT |
| Sep. 01 | UK regulator suspends rare-disease drug Tavneos for new patients over unreliable data | RE |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AMGN Stock
- Consensus Amgen Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
